Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:3/7/2011

CAMBRIDGE, Mass., March 7, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the Roth 23rd Annual Growth Stock Conference on Monday, March 14, 2011 at 12:00 p.m. PT at the Ritz Carlton Laguna Niguel in Dana Point, California and at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011 at 11:15 a.m. ET at the Loews Miami Hotel, Florida.

The live and archived webcasts of the company presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com.  Please log in approximately 5-10 minutes before each event to ensure a timely connection.  The archived replays will be available on the Idenix website for two weeks following the conferences.  

About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com.Idenix Pharmaceuticals Contact:Kelly Barry (617) 995-9033 (media)Eric Hoffman (617) 224-4485 (investors)
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
2. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
4. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
7. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
10. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , July 21, 2017 Did you know that PhRMA ... 2016? Or that combined spending on brand medicines, generics and the ... with brands accounting for just half of this (7 percent)? Or ... thirds of the world,s venture capital investments in high-growth biopharmaceutical startups? ... ...
(Date:7/19/2017)... , July 19, 2017  Mako Medical Laboratories partnered ... the Military Family Assistance Fund (MFA) to bring 140 ... to visit with their families one last time before ... coordinate the travel and logistics needed for these soldiers. ... soldiers and their families. We just wish we could ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based biotechnology company ... the completion of a $12.7 million Series A financing round. ... as the participation of existing investors. ... of New Ventures III and our current investors, and view ... of our platform technology to transform the course of PD ...
Breaking Medicine Technology:
(Date:7/21/2017)... , ... July 21, 2017 , ... “Kids aren't born ... to tie their shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company ... which launches on Kickstarter on Monday, July 21st. , The kit uses colorful, ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... (ACL) offer patients improved quality of life five years after injury, according to ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five years ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia ... that progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and ... and relapse. With such a challenging diagnosis that requires immediate action, patients ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... a telemedicine platform, in which their iMedSecure™ comes included with each system installation. ... encrypted live images to remote participants for real-time collaboration and immediate decision-making requirements. ...
(Date:7/20/2017)... ... , ... Girl Up Campaign Director, Melissa Kilby, released the ... of providing girls access to education in refugee settings. In May, Congressman Steve Chabot ... to Education in Vulnerable Settings Act.” Yesterday, companion legislation was introduced in the ...
Breaking Medicine News(10 mins):